Deutsche Bank AG Raises Position in Altimmune, Inc. $ALT

Deutsche Bank AG lifted its stake in Altimmune, Inc. (NASDAQ:ALT) by 3.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 79,851 shares of the company’s stock after purchasing an additional 3,026 shares during the quarter. Deutsche Bank AG owned about 0.10% of Altimmune worth $399,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. Ameriprise Financial Inc. raised its holdings in Altimmune by 35.6% during the 4th quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company’s stock valued at $37,888,000 after buying an additional 1,378,854 shares during the period. RFG Advisory LLC purchased a new stake in shares of Altimmune in the first quarter valued at $1,622,000. Millennium Management LLC raised its stake in shares of Altimmune by 139.8% in the fourth quarter. Millennium Management LLC now owns 345,637 shares of the company’s stock valued at $2,492,000 after acquiring an additional 201,484 shares during the period. Federated Hermes Inc. bought a new stake in shares of Altimmune in the 1st quarter worth about $939,000. Finally, Two Sigma Investments LP boosted its stake in shares of Altimmune by 33.2% during the 4th quarter. Two Sigma Investments LP now owns 605,303 shares of the company’s stock worth $4,364,000 after purchasing an additional 151,001 shares during the period. Institutional investors own 78.05% of the company’s stock.

Altimmune Trading Up 1.1%

ALT stock opened at $3.71 on Friday. Altimmune, Inc. has a 12-month low of $2.90 and a 12-month high of $11.16. The business’s 50-day moving average is $4.18 and its 200 day moving average is $5.08. The company has a current ratio of 20.44, a quick ratio of 20.44 and a debt-to-equity ratio of 0.09. The stock has a market cap of $327.43 million, a price-to-earnings ratio of -3.14 and a beta of -0.01.

Altimmune (NASDAQ:ALT) last released its earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.05. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative return on equity of 62.63% and a negative net margin of 438,730.03%. On average, sell-side analysts anticipate that Altimmune, Inc. will post -1.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on ALT. The Goldman Sachs Group upgraded shares of Altimmune to a “strong sell” rating in a report on Thursday, July 10th. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a report on Wednesday, August 13th. Wall Street Zen upgraded Altimmune from a “sell” rating to a “hold” rating in a report on Saturday, August 9th. JMP Securities dropped their price objective on Altimmune from $25.00 to $15.00 and set a “market outperform” rating for the company in a report on Thursday, July 10th. Finally, B. Riley cut their price objective on Altimmune from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 13th. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $17.40.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.